Search clinical trials for: Oral Treprostinil

Total 8262 results

United Therapeutics

Terminated

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

Pulmonary Hypertension Associated With HFpEF

United States
United Therapeutics

Completed

An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension (FREEDOM-EXT)

Pulmonary Arterial Hypertension

United States, Canada, India, United Kingdom, Spain, Israel, Australia, Belgium, France, Austria, China, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Sweden
United Therapeutics

Completed

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
United Therapeutics

Terminated

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

Pulmonary Hypertension | Heart Failure With Preserved Ejection Fraction

United States
United Therapeutics

Active, not recruiting

ADAPT - A Patient Registry of the Real-world Use of Orenitram® (ADAPT)

Pulmonary Arterial Hypertension

United States
United Therapeutics

Completed

FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Pulmonary Hypertension

United States, China, Israel, Belgium, Canada, France, India, Mexico, Austria, Italy, Netherlands, Poland, Puerto Rico
United Therapeutics

Withdrawn

Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)

Pulmonary Hypertension Associated With Sickle Cell Disease
United Therapeutics

Withdrawn

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Pulmonary Fibrosis | Pulmonary Hypertension

United States
Stanford University
United Therapeutics

Completed

Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis

Systemic Sclerosis | Calcinosis

United States
United Therapeutics

Withdrawn

Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH

Pulmonary Arterial Hypertension
United Therapeutics

Completed

Effect of Food on the Pharmacokinetics of Oral Treprostinil

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States
Brigham and Women's Hospital
United Therapeutics

Completed

Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon

Raynaud's Phenomenon

United States
AOP Orphan Pharmaceuticals AG
GCP-Service International Ltd. & Co. KG; ANOVA CRO s.r.o.; PharmaLex Belgium; Aixial...

Recruiting

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients (TripleTRE)

Pulmonary Arterial Hypertension

Austria, Spain, France, Germany, Italy, Czechia, Hungary, Poland, Portugal, Romania
United Therapeutics
Lung Biotechnology PBC

Recruiting

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension (ARTISAN)

Pulmonary Arterial Hypertension

United States
United Therapeutics

Completed

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

PAH

United States
Southern Arizona Vascular Institute
Southern Illinois University

Unknown

UT-15C SR in the Treatment of Critical Limb Ischemia

Critical Limb Ischemia

United States
United Therapeutics

Withdrawn

Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension
United Therapeutics

Completed

FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

Pulmonary Hypertension

United States, United Kingdom, Canada, Spain, Australia, Israel, Germany, Belgium, France, Austria, Italy, Poland, Ireland, Netherlands
United Therapeutics

Completed

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States
United Therapeutics

Enrolling by invitation

Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-OLE)

Idiopathic Pulmonary Fibrosis | Interstitial Lung Disease

United States, Spain, Australia, Taiwan, Israel, Korea, Republic of, Belgium, France, Argentina, Chile, Denmark, Mexico
United Therapeutics

Recruiting

Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-2)

Idiopathic Pulmonary Fibrosis | Interstitial Lung Disease

Taiwan, Belgium, Spain, Korea, Republic of, Germany, Australia, Chile, Denmark, France, Mexico, Israel, Italy, Netherlands, Argentina, New Zealand, Peru
Insmed Incorporated

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants

Healthy Volunteers

United States
United Therapeutics

Terminated

Open-Label Study of Oral Treprostinil in Digital Ulcers (DISTOL-EXT)

Systemic Sclerosis

United States, Canada, United Kingdom
United Therapeutics

Recruiting

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Interstitial Lung Disease | Progressive Pulmonary Fibrosis

United States, Canada
SciPharm SàRL

Completed

Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH) (CTREPH)

Non-operable Chronic Thromboembolic Pulmonary Hypertension

Austria, Poland, Czechia, Germany
United Therapeutics

Completed

Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities

Pulmonary Arterial Hypertension

United States
Insmed Incorporated

Terminated

A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States
United Therapeutics

Completed

Three Times Daily Dosing of UT-15C

Healthy

United States
United Therapeutics

Terminated

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Pulmonary Hypertension | Interstitial Lung Disease | Combined Pulmonary Fibrosis and Emphysema

United States, Puerto Rico
Mannkind Corporation

Completed

Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

Pulmonary Arterial Hypertension

United States
Liquidia Technologies, Inc.
Nuventra, Inc.

Completed

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil (INSPIRE)

Primary Pulmonary Hypertension

United States
Insmed Incorporated

Recruiting

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Argentina, Brazil, Germany, Italy, Malaysia, Philippines, Spain, United Kingdom, Serbia, Japan, United States, Mexico
Ascendis Pharma A/S

Terminated

A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in Healthy Adult Male Volunteers

Healthy Volunteers
United Therapeutics

Withdrawn

Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers

PAH

United States
United Therapeutics

Withdrawn

Inhaled Treprostinil for PAH: Open-label Extension (INTREPID - OL)

Pulmonary Arterial Hypertension
United Therapeutics

Recruiting

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON)

Idiopathic Pulmonary Fibrosis | Interstitial Lung Disease

United States, Canada
Mardi Gomberg -Maitland MD, MSc
Ohio State University; Allegheny Singer Research Institute (also known as Allegheny...

Withdrawn

Telemonitoring to Treat Group 2 Pulmonary Hypertension (RECAPTURE)

Pulmonary Hypertension Due to Left Heart Disease

United States
United Therapeutics

Completed

Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis (DISTOL-PK)

Systemic Sclerosis

United States
Liquidia Technologies, Inc.
Nuventra, Inc.

Active, not recruiting

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

Primary Pulmonary Hypertension

United States
AOP Orphan Pharmaceuticals AG

Not yet recruiting

Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH

Pulmonary Arterial Hypertension

Spain, Austria, France, Hungary
Insmed Incorporated

Completed

A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Pulmonary Hypertension

Belgium, Germany, Spain, Argentina, Australia, Italy, United Kingdom
United Therapeutics

Completed

TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) (TRUST-2)

Pulmonary Arterial Hypertension
United Therapeutics

Completed

An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Korea, Republic of, United States, Australia, Austria, Taiwan, China, Israel, Canada, India, Germany, Singapore, United Kingdom, Brazil, Italy, Netherlands, Argentina, Sweden, Chile, Denmark, France, Greece, Mexico, Poland
Lung Biotechnology PBC

Terminated

Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis | Pulmonary Hypertension

United States
United Therapeutics
Lung Biotechnology PBC

Terminated

Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD) (PERFECT OLE)

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States, Israel
University of Colorado, Denver

Completed

Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1 (TAPIT-1)

Pulmonary Hypertension | COPD

United States
Ferrer Internacional S.A.

Available

Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease

Pulmonary Hypertension | Interstitial Lung Disease | Combined Pulmonary Fibrosis and Emphysema
United Therapeutics
CVie Therapeutics Co. Ltd.

Withdrawn

An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

China
United Therapeutics

Completed

Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension (FREEDOM-C2)

Pulmonary Hypertension

United States, Canada, Germany, Spain, Belgium, Sweden, Israel, France, Italy, Netherlands, Portugal, United Kingdom
United Therapeutics

Completed

Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy (FREEDOM-EV)

Pulmonary Arterial Hypertension

Korea, Republic of, United States, Australia, Austria, Taiwan, China, Israel, Canada, India, Germany, Singapore, United Kingdom, Brazil, Italy, Netherlands, Argentina, Sweden, Chile, Denmark, France, Greece, Mexico, Poland

Search clinical trials for: Oral Treprostinil

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations